In a bid to bolster its targeted protein degradation approach, Astellas has entered into a collaboration and licensing agreement with PeptiDream worth up to US$312.6 M. The agreement will provide Astellas access to PeptiDream’s peptide discovery platform system (PDPS™) to develop drug candidates for two undisclosed targets identified by Astellas. This deal comes just a month after the announcement of Astellas’ agreement with Cullgen to gain access to the latter’s uSMITE™ targeted protein degradation platform for a total deal value of US$1.9 B.